A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer

Status:
Active, not recruiting

Trial end date:
2022-09-20

Target enrollment:

Participant gender:

The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.

Phase 3

Eli Lilly and Company

Erlotinib Hydrochloride